NVO
AGM season, but make it dramatic
Novo Nordisk’s 2026 annual general meeting wasn’t just a rubber-stamp affair. The company said Mike Doustdar has been appointed President and CEO, which is a pretty big deal for a drugmaker that’s been living in the market’s spotlight thanks to its obesity and diabetes empire.
New faces at the top
The boardroom also got a refresh. Lars Rebien Sørensen was re-elected chair, Cees de Jong stayed on as vice chair, and the board added Helena Saxon, Jan van de Winkel, and Ramona Sequeira. Employee-elected board members also joined for a four-year term — because apparently even megacaps need a little governance spring cleaning.
Why investors should care
CEO changes can be like swapping captains mid-voyage: the ship keeps moving, but everyone starts asking what the next course correction looks like. For Novo, that matters because the stock is heavily tied to execution on blockbuster GLP-1 drugs, pricing pressure, and how aggressively management pushes the next growth chapter.
Big picture: this isn’t a revenue surprise, but it is a control-room change. And for a company this important, the person at the helm can move sentiment almost as much as a data readout.